Key Blockbuster Drugs About to Get Generic Rivals

This is week-old news, but worth repeating.

Key blockbuster drugs about to get generic rivals
These are blockbuster drugs, with more than $1 billion in annual global sales, set to go off patent and get generic competition in the U.S. in the next two years:
Patent ends Brand name Generic name Use/conditions treated Made/sold by
Oct. 2011 Zyprexa olanzapine schizophrenia/bipolar Eli/Lilly
Nov. 2011 Lipitor atorvastatin high cholesterol Pfizer
March 2012 Lexapro escitalopram depression Forest/Labs
March 2012 Seroquel quetiapine schizophrenia/bipolar AstraZeneca
March 2012 Avapro/Avalide irbesartan high blood pressure Bristol-Myers/Sanofi
April 2012 Provigil modafinil narcolepsy Cephalon
May 2012 Plavix clopidogrel clot prevention Bristol-Myers/Sanofi
July 2012 Tricor fenofibrate high triglycerides Abbott
Aug. 2012 Singulair montelukast asthma/allergies Merck
Aug. 2012 Actos pioglitazone diabetes Takeda
Sept. 2012 Diovan valsartan high blood pressure Novartis
Sept. 2012 Geodon ziprasidone bipolar disorder Pfizer
Nov. 2012 Lidoderm lidocaine pain patch Endo
Dec. 2012 Atacand candesartan heart failure AstraZeneca
March 2013 Lovaza omega-3 acid high triglycerides GlaxoSmithKline
Aug. 2013 Temodar temozolomide brain tumors Merck
Note: Patent expiration/generic arrival dates can change due to litigation or regulatory issues.Sources: Medco Health Solutions, company websites.

Wow. I can’t believe it took that long for some of those to get generic counterparts. I was on Singulair and Provigil back in 2001. Then, they put me on that *evil* Lexapro in 2003. Was that new then? I have some serious bones to pick with that doctor I had back then and I think I’m about to add, “Put patients health and well-being at risk for kick-backs from pharmacuticial companies.”

I love this post, even though I didn’t find it until just now. The drug companies fight like cats to keep their patent, but eventually must give up in the end. But they don’t go down without a fight. Look at the stats–it’s amazing how long they’re able to hold on to patents!


Leave a Reply

Abilify in Court – July 2017 Update

It’s been five years since I wrote, Success! I’ve Quit Abilify.  Since then, the post has received over 3500 views.  And all told, views for posts (linked below) related to the BS I endured while taking Abilify total over 49,000. The struggle is real. I haven’t posted for over a …

Polypharmacy and Bipolar Disorder

How many meds do you use to treat your bipolar disorder?  And your co-morbid afflictions?  Personally, I get off easy and take only four. In the treatment of bipolar disorder, polypharmacy (the use of multiple meds to treat a disease or disorder) is the norm.  And generally, bipolar I patients …

Heritable bipolar phenotypes pinned down

(I don’t usually quote an entire article, but this subject is near and dear to my heart….) Heritable bipolar phenotypes p inned down Published on February 14, 2014 at 5:12 PM By Eleanor McDermid, Senior medwireNews Reporter   A large study has pinpointed brain and behavioural traits that are genetically influenced and …

error: Content is protected !!